A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

Trial Details

NCT ID

NCT06362252

Phase

PHASE1 / PHASE2

Sponsor

Daiichi Sankyo

Status

RECRUITING

Cancer Type

Small Cell (SCLC) Lung Cancer

Interventions

Ifinatamab deruxtecan
Atezolizumab
Carboplatin

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Phoenix, Arizona, United States|33.44838,-112.07404
Los Angeles, California, United States|34.05223,-118.24368
Newport Beach, California, United States|33.61891,-117.92895
Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

Inclusion Criteria
Participants must meet all of the following criteria to be eligible for enrollment into the study:
Sign and date the informed consent form (ICF), prior to the start of any study-specific qualification procedures.
Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →